IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 7763616 B1

PDFFull Text
Date of Patent:
Jul. 27, 2010

Filed:

Feb. 14, 2006

Piperazine-piperidines with cxcr3 antagonist activity

Applicants:

Wensheng Yu, Edison, NJ (US);

Seong Heon Kim, Livingston, NJ (US);

Gopinadhan N. Anilkumar, Edison, NJ (US);

Stuart B. Rosenblum, West Orange, NJ (US);

Bandarpalle B. Shankar, Branchburg, NJ (US);

Brian F. Mcguinness, Plainsboro, NJ (US);

Douglas W. Hobbs, Yardley, PA (US);

Yuefei Shao, Princeton, NJ (US);

Inventors:

Wensheng Yu, Edison, NJ (US);

Seong Heon Kim, Livingston, NJ (US);

Gopinadhan N. Anilkumar, Edison, NJ (US);

Stuart B. Rosenblum, West Orange, NJ (US);

Bandarpalle B. Shankar, Branchburg, NJ (US);

Brian F. McGuinness, Plainsboro, NJ (US);

Douglas W. Hobbs, Yardley, PA (US);

Yuefei Shao, Princeton, NJ (US);

Assignee:

Schering Corporation, Kenilworth, NJ (US);

Attorneys:

Palaiyur S. Kalyanaraman

Krishna G. Banerjee

Primary Examiner:

Mark L Berch

Assistant Examiner:

Cecilia M Jaisle

Int. Cl.
CPC ...
A61K 31/5025 (2006.01); A61K 31/4985 (2006.01); C07D 245/02 (2006.01); C07D 255/02 (2006.01); C07D 257/08 (2006.01); C07D 259/00 (2006.01); C07D 239/04 (2006.01); C07D 239/70 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); A61K 31/497 (2006.01); C07D 241/36 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); A61P 29/00 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 3/10 (2006.01); A61P 31/08 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Find Patent Forward Citations

Loading…